GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NeurogesX Inc (OTCPK:NGSX) » Definitions » Cyclically Adjusted Revenue per Share

NeurogesX (NeurogesX) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2011)


View and export this data going back to . Start your Free Trial

What is NeurogesX Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NeurogesX's adjusted revenue per share data for the fiscal year that ended in Dec. 2011 was $0.500. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2011.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-25), NeurogesX's current stock price is $ 0.005. NeurogesX's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2011 was $0.00. NeurogesX's Cyclically Adjusted PS Ratio of today is .


NeurogesX Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for NeurogesX's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeurogesX Cyclically Adjusted Revenue per Share Chart

NeurogesX Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeurogesX Semi-Annual Data
Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeurogesX's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, NeurogesX's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeurogesX's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NeurogesX's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NeurogesX's Cyclically Adjusted PS Ratio falls into.



NeurogesX Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NeurogesX's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2011 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2011 (Change)*Current CPI (Dec. 2011)
=0.5/95.2134*95.2134
=0.500

Current CPI (Dec. 2011) = 95.2134.

NeurogesX Annual Data

Revenue per Share CPI Adj_RevenuePerShare
200212 0.000 76.324 0.000
200312 0.000 77.758 0.000
200412 0.000 80.290 0.000
200512 0.000 83.032 0.000
200612 0.000 85.142 0.000
200712 0.000 88.616 0.000
200812 0.000 88.697 0.000
200912 0.114 91.111 0.119
201012 0.465 92.474 0.479
201112 0.500 95.213 0.500

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


NeurogesX  (OTCPK:NGSX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NeurogesX Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of NeurogesX's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NeurogesX (NeurogesX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
NeurogesX, Inc. was incorporated in California as Advanced Analgesics, Inc. on May 28, 1998 and changed its name to NeurogesX, Inc. in September 2000. In February 2007, it reincorporated into Delaware. It is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. It is assembling a portfolio of pain management product candidates based on known chemical entities to develop innovative new therapies that might offer substantial advantages over currently available treatment options. The Company's initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company's first commercial product, Qutenza, the first prescription strength capsaicin product is a dermal delivery system designed to treat certain neuropathic pain conditions and was approved by the U.S, Food and Drug Administration, or FDA in November 2009 for the management of neuropathic pain associated with postherpetic neuralgia, or PHN. It is currently preparing to commercialize Qutenza in the United States with its own sales force and that Qutenza would be commercially available in the United States in the first half of 2010. Qutenza is a non-narcotic analgesic formulated in a localized treatment patch containing an 8% concentration of synthetic capsaicin. Capsaicin is released from the patch and, with the aid of penetration enhancers, penetrates into the skin during application without significant absorption of capsaicin into the bloodstream. The users of Qutenza are unlikely to experience the common central nervous system side effects of systemically administered drugs used to treat neuropathic pain such as anti-convulsants, anti-depressants and opioids and the potential for abuse and addiction associated with some of these drugs. It is currently evaluating the nature, scope and timing of continued development of Qutenza to support the potential for label expansion in the United States. Areas of potential focus for label expansion include HIV-distal sensory neuropathy, or HIV-DSP, also known as HIV-associated neuropathy, or HIV-AN, painful diabetic neuropathy, or PDN, and potentially other neuropathic pain indications. It expects that Qutenza would compete against, and may be used in combination with, well-established products currently used both on and off-label in its target indications. The most directly competitive currently marketed products in the United States are Lidoderm, an FDA-approved 5% lidocaine topical patch for the treatment of PHN marketed by Endo Pharmaceuticals, and Lyrica, an oral anti-convulsant, marketed by Pfizer for use in the treatment of PHN. Regulation by governmental authorities in the United States and other countries is a significant factor in the development, manufacture and marketing of pharmaceuticals.
Executives
Ron Martell officer: President and CEO PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Stephen F Ghiglieri officer: Exec. V.P., COO & CFO C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Steven H Nelson director 21650 OXNARD STREET, WOODLAND HILLS CA 91367
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Bradford S Goodwin director 5000 SHORELINE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Anthony A Ditonno director, officer: President and CEO C/O OXYGEN BIOTHERAPEUTICS, INC., ONE COPLEY PARKWAY, STE. 490, MORRISVILLE NC 27560
Jeffrey K Tobias officer: CMO, EVP Research & Deve C/O NEUROGESX INC, 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Moshe Arkin 10 percent owner, other: also member of 10% owner group 6 HACHOSHLIM ST., HERZELIA L3 4672406
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Clinton Bybee 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Steven Lazarus 10 percent owner 8755 WEST HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners V Llc 10 percent owner C/O ARCH VENTURE PARTNERS, 8755 W. HIGGINS AVE. #1025, CHICAGO IL 60631

NeurogesX (NeurogesX) Headlines

From GuruFocus

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-13-2010

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-08-2010

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-11-2010